Abstract
Drosophila melanogaster multisubstrate deoxyribonucleoside kinase (Dm-dNK) can additionally sensitize human cancer cell lines towards the anti-cancer drug gemcitabine. We show that this property is based on the Dm-dNK ability to efficiently phosphorylate gemcitabine. The 2.2 angstrom resolution structure of DmdNK in complex with gemcitabine shows that the residues Tyr70 and Arg105 play a crucial role in the firm positioning of gemcitabine by extra interactions made by the fluoride atoms. This explains why gemcitabine is a good substrate for Dm-dNK(. (C) 2009 Elsevier Inc. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 430-433 |
| Number of pages | 4 |
| Journal | Biochemical and Biophysical Research Communications |
| Volume | 382 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Nucleoside analogs
- Deoxyribonucleoside kinase
- Gene-therapy
- Cancer
- Salvage pathway
- Structure-function relationship
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver